Canadian Securities ExchangeThe Daily Bell
Podcasts

Timothy Ko on Treating Addiction with DMT and Psychedelics | The CSE Podcast Ep3-S2

September 10, 20211 min read

CSE’s Barrington Miller catches up with Timothy Ko, CEO of Entheon Biomedical Corp. (CSE:ENBI) to discuss how his company is pursuing R&D of DMT-based products to safely treat addiction. Timothy provides an update on what the company has accomplished in the year since they’ve been public and upcoming plans for clinical trials.

Here’s an overview of what Barrington and Timothy cover in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Catching up with Timothy Ko and Entheon Biomedical
2:30 – What has happened since they listed on the CSE – Canadian Securities Exchange
4:12 – Personalization through genetics
6:20 – The genetics test kit
8:30 – Pathway for clinical trials
9:55 – What’s coming next for investors

About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.  

Learn more about Entheon Biomedical Corp. at Entheon Biomedical Corp. | CSE – Canadian Securities Exchange (thecse.com)

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Keep Reading

Read the blog

Jan 12, 2022Podcasts

Adriana Kertzer on Representing the Power of the Plant | The CSE Podcast Ep9-S2

CSE’s Barrington Miller is joined by Adriana Kertzer, Co-Founder of Plant Medicine Law Group, to discuss the unique aspects of representing clients in the cannabis and psychedelics sectors, ongoing policy and regulation issues, and what makes their law firm different from others in this space. The conversation also highlights Adriana’s thoughts on how she sees…

Nov 18, 2021Podcasts

Anthony Durkacz on Building a Turnaround at FSD Pharma | The CSE Podcast Ep6-S2

CSE’s Barrington Miller is joined by Anthony Durkacz, Interim CEO of FSD Pharma (CSE:HUGE) to discuss the company’s recent history and transition from the cannabis-era to new opportunities in the growing psychedelics space. Here’s an overview of what Barrington and Anthony discuss in this edition of the “Exchange for Entrepreneurs” podcast: 0:00 – Introducing Anthony…

(CSE:HUGE)